YOU ARE EXPLORING
Oncology Clinical applications Risk Assessment & Early Detection
Clinical applications | Testing guidance

Risk Assessment & Early Detection

Distinguish inherited cancer susceptibility from screening and early detection. Test selection must be driven by individual and family history, not a universal testing package.

Clinical overview

Clinical purpose and scope

Two distinct questions arise: does a person have an inherited predisposition to cancer, and is there evidence of a current malignancy? Germline testing addresses inherited susceptibility; established screening aims to detect cancer. Multi-cancer early detection (MCED) tests remain under clinical evaluation and do not replace standard screening.

Assay selection notes

The listed assays are examples, not confirmed available services. Clinical indications, assay validation, and specimen requirements must be checked with the laboratory.

Scenario-based test selection

Tests to consider in different scenarios

Examples for discussion with an oncologist; test selection must reflect the clinical circumstances of each patient.

01

Strong family history or young-onset cancer

Multiple relatives with breast or ovarian cancer, early colorectal cancer, or several related cancers in one family.

Suggested assay or pathway

Genetic counseling followed by an appropriate hereditary-cancer germline panel based on the pedigree; targeted familial-variant testing when a known variant exists.

Rationale and caveats

An inherited syndrome can change surveillance for the patient and relatives. A negative result does not necessarily eliminate inherited risk.

02

Ovarian, pancreatic, or metastatic prostate cancer

A patient with cancer may require hereditary-risk assessment in addition to treatment selection.

Suggested assay or pathway

Consider germline BRCA1/2 or a suitable multigene panel after clinical assessment; order somatic tumor testing separately when indicated.

Rationale and caveats

Germline and somatic tests answer different questions. A tumor BRCA finding does not establish inheritance and may warrant germline evaluation.

03

Asymptomatic person at average risk

An individual with no identified high-risk family history requests a general cancer assessment.

Suggested assay or pathway

Use age- and risk-appropriate, guideline-based screening, such as mammography or colorectal screening. Discuss MCED only with its evidence gaps, limitations, and research context.

Rationale and caveats

MCED does not definitively diagnose or exclude cancer; false positive and false negative findings may lead to additional investigations.

04

Family with a known pathogenic variant

A family member carries a confirmed pathogenic or likely pathogenic inherited variant.

Suggested assay or pathway

Offer cascade testing for the specific familial variant with genetic counseling.

Rationale and caveats

Targeted cascade testing is often more appropriate than starting broad panels in every relative.

Related assays

Related assays and their uses

Each entry specifies the sample, testing goal, and clinical context to avoid confusion.

Hereditary Cancer PanelClinically indicated

Hereditary cancer germline panel

Eligible individuals with suggestive personal or family history

Specimen / data: Blood or saliva
BRCA1/2 GermlineClinically indicated

Germline BRCA1/2 testing

Personal or family history consistent with hereditary breast/ovarian cancer

Specimen / data: Blood or saliva
MMR Germline PanelClinically indicated

Lynch syndrome germline panel

Suspected Lynch syndrome based on clinical and, where appropriate, tumor findings

Specimen / data: Blood or saliva
Targeted Cascade TestingClinically indicated

Familial-variant cascade test

Relatives of a carrier of a known inherited variant

Specimen / data: Blood or saliva
MMR IHC / MSIComplementary tumor test

Tumor MMR/MSI screening

Investigating mismatch repair deficiency in selected tumors, including colorectal or endometrial cancer; not a germline diagnosis

Specimen / data: Tumor tissue
Multi-Cancer Early DetectionEmerging; limited evidence of clinical benefit

Multi-cancer early detection (MCED)

Molecular signal detection across multiple cancers in asymptomatic populations; not a substitute for standard screening

Specimen / data: Usually blood
Before ordering

Required information and expected report

Define the relevant clinical information and expected report components before discussing testing with the scientific team.

Required inputs

Detailed personal/family cancer history, ages at diagnosis, and degree of relationship

Previous germline and tumor testing results, if available

Purpose of testing: risk assessment, suspected hereditary syndrome, or screening

Expected reporting elements

Reportable germline variants with standard classifications and assay coverage limitations

Explanation of what each finding does and does not establish about inherited risk

Recommendations for genetic counseling and cascade testing when indicated

Interpretation and evidence

Interpretation and limitations

• Germline tests are not designed to detect the current presence of a tumor.

• MCED is not suitable for definitively ruling out cancer or replacing mammography, colonoscopy, and other established screening methods.

• Genetic test selection and communication with relatives require informed consent and appropriate genetic counseling.

Need guidance on choosing an appropriate test?

Describe the clinical question and available data in the support form; do not send patient identifiers.

Contact specialist support →
WhatsAppCall usGet expert consultation